HealthcarePress Releases

Intranasal Drug Delivery Devices Market Size To Worth USD 2.98 billion by 2030

Share This Article

global intranasal drug delivery devices market was evaluated at USD 1.17 billion in 2020 and is speculated to accrue USD 2.98 billion by 2030, growing at 12.8% CAGR between 2021-2030.

Latest Research Study on ” intranasal drug delivery devices Market – Global Industry Analysis, Market Size, Share, Growth, Trends, Region Outlook, And Segment Forecasts, 2021 – 2030″.

Download Free Sample Copy with TOC, Graphs & List of Figures @ https://www.precedenceresearch.com/sample/1253

This research report evaluates the intranasal drug delivery devices market on a global and regional level. It offers a thorough analysis of the market revenue status, growth, future trends, and forecast of the global intranasal drug delivery devices market for the period from 2017 to 2030.

Growth Factors

Factors such as growing patient preference for nasal drug delivery and increasing popularity of self-administration of medications are driving the growth of intranasal drug delivery devices market. High incidence of cardiovascular disorders, increased cancer and diabetes cases, amplified focus on elderly and pediatric patients, and growing demand for home-based healthcare devices are further propelling the intranasal drug delivery devices market expansion across the globe. Additional aspects that are anticipated to fuel this industry are rapid R&D activity and reception of new drug delivery approaches and equipment’s, reformulation of injections and oral medications into the preparations to be administered by the nasal route, and quick onset of action. The simple administration and improved efficacy have amplified patient preference for the nasal drug delivery which subsequently has enhanced the demand for overall market for the nasal drug delivery devices market.

Due to the greater permeability and low enzymatic environment of the nasal cavity, and evasion of the hepatic first pass metabolism, intranasal drug delivery devices are appropriate for systemic transport of drug molecule through nose. Numerous drug delivery devices for nasal use of solid, semisolid, and liquid formulation are examined to deliver the medications to the treat most critical CNS diseases (i.e., Alzheimer’s disease, Parkinson’s disease) since it requires quick and specific aiming of medications to the brain.

Market Report Scope

Report Highlights Details
Market Size US$ 2.98 Billion by 2030
Growth Rate CAGR of 12.8% from 2021 to 2030
Base Year 2020
Historic Data 2017 to 2020
Forecast Period 2021 to 2030

For More Information or Customization Before Buying, Visit @ https://www.precedenceresearch.com/customization/1253

This report enables readers to make important decisions with regard to their business, with the help of a wealth of Information enclosed in the study. The report also provides the compound annual growth rate (CAGR) of the global intranasal drug delivery devices market for the forecast period of 2021–2030. This data can help readers interpret quantitative growth aspects of the global market during the forecast period. It presents a wealth of information on key market dynamics, including drivers, market trends, and challenges, as well as the structure of the global market across the globe.

The report analyzes the historical and present-day scenario of the global intranasal drug delivery devices market to accurately gauge its growth potential. The study presents detailed information about important growth factors, restraints, and key trends that are creating the landscape for growth of the global market in order to identify opportunities for stakeholders.

Key Highlights

  • Among the system segment, multi-dose systems are expected to dominate the overall market. Multi-dose systems have multiple advantages over other systems which makes them a system of choice in many settings.
  • The non-pressurized containers accounted for the largest revenue in the containers segment with more than 68% share in 2019. Increasing awareness regarding the use of non-pressurized containers is the major reason for high market share of non-pressurized containers. Pressurized containers are expected to grow at the topmost CAGR during the forecast time-frame.
  • Asthma accounted for the largest revenue in the application segment. Increasing prevalence of asthma in developing regions is the key reason for high market share of asthma.
  • Hospitals accounted for the largest revenue in the end-user segment. High frequency of intranasal drug delivery in hospitals is the key reason for high market share of hospitals.
  • Teleflex Incorporated accounted for a significant share of the global intranasal drug delivery devices market.
  • The report covers data for North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. In 2020, North America dominated the global market with a market share of more than 37%.
  • Europe was the second important market chiefly due to presence of latest healthcare infrastructure and high investment in research and development.
  • Asia Pacific is anticipated to grow at the maximum CAGR of around 14% in the forecast period due to high incidence of cancer. Latin America and the African and Middle Eastern region will display noticeable growth.

Purchase Full Research Report (Single User License US$ 4500) @ https://www.precedenceresearch.com/checkout/1253

Competition Landscape

In the final section of the research report, Precedence Research provided the global intranasal drug delivery devices market structure and a detailed competition landscape to provide a dashboard view of key players operating in the global market along with their business strategies to report audiences. This section is primarily designed to provide clients with an objective and detailed comparative assessment of the key providers specific to a market segment in the value chain of the market.

Some of the major players in the intranasal drug delivery devices market include:

  • Johnson & Johnson, Inc.
  • Aptar Pharma Group
  • GlaxoSmithKline Plc
  • Aegis Therapeutics LLC
  • H&T Presspart Manufacturing Ltd.
  • AstraZeneca Plc
  • Becton, Dickinson and Company
  • Novartis AG
  • Teleflex Incorporated
  • Vectura Group Plc.

Market Segmentation

By System

  • Metered Dose
  • Multi-Dose Systems
  • Unit-Dose Systems

By Container

  • Non-Pressurized Containers
  • Pressurized Containers

By Application

  • Chronic Obstructive Pulmonary Disease (COPD)
  • Rhinitis
  • Cystic Fibrosis
  • Nasal Congestion
  • Asthma
  • Others

By End User

  • Ambulatory Surgical Centers
  • Clinics
  • Hospitals
  • Others

Regional Segmentation

– North America (U.S. and Canada)

 – Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)

 – Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)

 – Latin America (Brazil and Rest of Latin America)

– Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)

Research Methodology

  • Market estimate for 2020
  • Average selling price (ASP) per region for specific product type
  • Filtrations and assortment of gathered data, to estimate the base year (2021) market size for the country
  • Gathering data from company websites, annual reports, white papers, financial reports, broker reports, investor presentations, and SEC filings
  • National government documents, statistical databases
  • News articles, press releases, and webcasts specific to companies operating in the market
  • Country wise analysis through internal and external proprietary databases, and relevant patent and regulatory databases
  • Determination of market penetration by country

Most Asked Questions –

What was the market size value of the intranasal drug delivery devices in 2020?

What is the expected market size by 2030?

What is the intranasal drug delivery devices market growth?

What are the key factors that positively influence market growth?

Who are the prominent players in the intranasal drug delivery devices market?

Why Buy this Report?

The purpose of Precedence Research’s intranasal drug delivery devices market study is to provide stakeholders with a detailed picture of potential barriers and untapped opportunities. The report contains exclusive information to assist businesses in making informed decisions about how to maintain growth throughout the assessment period.

TABLE OF CONTENT

Chapter 1.    Introduction

1.1.    Research Objective
1.2.    Scope of the Study
1.3.    Definition

Chapter 2.    Research Methodology

2.1.    Research Approach
2.2.    Data Sources
2.3.    Assumptions& Limitations

Chapter 3.    Executive Summary

3.1.    Market Snapshot

Chapter 4.    Intranasal Drug Delivery Devices Market Variables and Scope 

4.1.    Introduction
4.2.    Market Classification and Scope

Chapter 5.    COVID 19 Impact on Intranasal Drug Delivery Devices Market

5.1.    Covid-19: Intranasal Drug Delivery Devices Industry Impact
5.2.    Intranasal Drug Delivery Devices Business Impact Assessment: Covid-19
5.2.1.    Services Challenges/Disruption
5.2.2.    Market Trends and Intranasal Drug Delivery Devices Opportunities in the COVID-19 Landscape for Major Markets
5.3.    Strategic Measures against Covid-19
5.3.1.    Government Support and Initiative to Combat Covid-19
5.3.2.    Proposal for Intranasal Drug Delivery Devices Market Players to deal with Covid-19 Pandemic Scenario

Chapter 6.    Intranasal Drug Delivery Devices Market Dynamics Analysis and Trends

6.1.    Market Dynamics
6.1.1.    Market Drivers
6.1.1.1.    High prevalence of cardiovascular diseases
6.1.1.2.    Patent expiration of popular drugs, increased cases of cancer and diabetes
6.1.2.    Market Restraints
6.1.2.1.    Complications Associated with the Overuse
6.1.3.    Market Opportunities
6.1.3.1.    Growing adoption of self-administration practices
6.1.3.2.    Technological advancements

Chapter 7.    Global Intranasal Drug Delivery Devices Market: Competitive Landscape

7.1.1.    Company Market Share/Positioning Analysis
7.1.1.1.    Intranasal Drug Delivery Devices Market Revenue by Market Players (2016 -2019)
7.1.1.2.    Intranasal Drug Delivery Devices Market Revenue Market Share by Market Players (2016 -2019)
7.1.2.    Key Organic/Inorganic Strategies Adopted by Players
7.1.2.1.    Product Portfolio Expansion, Geographic Expansion, System Innovation
7.1.2.2.    Merger and Acquisition, Collaboration and Partnerships
7.1.3.    Market Players Landscape
7.1.3.1.    List of Suppliers
7.1.3.2.    List of End-users

Chapter 8.    Global Intranasal Drug Delivery Devices Market, By System

8.1.    Intranasal Drug Delivery Devices Market, by System, 2016-2027
8.1.1.    Metered Dose
8.1.1.1.    Market Revenue and Forecast (2016-2027)
8.1.2.    Multi-Dose Systems
8.1.2.1.    Market Revenue and Forecast (2016-2027)
8.1.3.    Unit-Dose Systems
8.1.3.1.    Market Revenue and Forecast (2016-2027)

Chapter 9.    Global Intranasal Drug Delivery Devices Market, By Container

9.1.    Intranasal Drug Delivery Devices Market, by Container, 2016-2027
9.1.1.    Non-Pressurized Containers
9.1.1.1.    Market Revenue and Forecast (2016-2027)
9.1.2.    Pressurized Containers
9.1.2.1.    Market Revenue and Forecast (2016-2027)

Chapter 10.    Global Intranasal Drug Delivery Devices Market, By Application

10.1.    Intranasal Drug Delivery Devices Market, by Application, 2016-2027
10.1.1.    Chronic Obstructive Pulmonary Disease (COPD)
10.1.1.1.    Market Revenue and Forecast (2016-2027)
10.1.2.    Rhinitis
10.1.2.1.    Market Revenue and Forecast (2016-2027)
10.1.3.    Cystic Fibrosis
10.1.3.1.    Market Revenue and Forecast (2016-2027)
10.1.4.    Nasal Congestion
10.1.4.1.    Market Revenue and Forecast (2016-2027)
10.1.5.    Asthma
10.1.5.1.    Market Revenue and Forecast (2016-2027)
10.1.6.    Others
10.1.6.1.    Market Revenue and Forecast (2016-2027)

Chapter 11.    Global Intranasal Drug Delivery Devices Market, By End User

11.1.    Intranasal Drug Delivery Devices Market, by End User, 2016-2027
11.1.1.    Ambulatory Surgical Centers
11.1.1.1.    Market Revenue and Forecast (2016-2027)
11.1.2.    Clinics
11.1.2.1.    Market Revenue and Forecast (2016-2027)
11.1.3.    Hospitals
11.1.3.1.    Market Revenue and Forecast (2016-2027)
11.1.4.    Others
11.1.4.1.    Market Revenue and Forecast (2016-2027)

Chapter 12.    Global Intranasal Drug Delivery DevicesMarket, Regional Estimates and Trend Forecast

12.1.    North America
12.1.1.    Market Revenue Forecast by System(2016-2027)
12.1.2.    Market Revenue Forecast by Container(2016-2027)
12.1.3.    Market Revenue Forecast by Application(2016-2027)
12.1.4.    Market Revenue Forecast by End User (2016-2027)
12.1.5.    U.S
12.1.5.1.    Market Revenue Forecast (2016-2027)
12.1.6.    Canada
12.1.6.1.    Market Revenue Forecast (2016-2027)
12.2.    Europe
12.2.1.    Market Revenue Forecast by System (2016-2027)
12.2.2.    Market Revenue Forecast by Container (2016-2027)
12.2.3.    Market Revenue Forecast by Application (2016-2027)
12.2.4.    Market Revenue Forecast by End User (2016-2027)
12.2.5.    UK
12.2.5.1.    Market Revenue Forecast (2016-2027)
12.2.6.    Germany
12.2.6.1.    Market Revenue Forecast (2016-2027)
12.2.7.    France
12.2.7.1.    Market Revenue Forecast (2016-2027)
12.2.8.    Rest of EU
12.2.8.1.    Market Revenue Forecast (2016-2027)
12.3.    Asia Pacific (APAC)
12.3.1.    Market Revenue Forecast by System (2016-2027)
12.3.2.    Market Revenue Forecast by Container (2016-2027)
12.3.3.    Market Revenue Forecast by Application (2016-2027)
12.3.4.    Market Revenue Forecast by End User (2016-2027)
12.3.5.    China
12.3.5.1.    Market Revenue Forecast (2016-2027)
12.3.6.    India
12.3.6.1.    Market Revenue Forecast (2016-2027)
12.3.7.    Japan
12.3.7.1.    Market Revenue Forecast (2016-2027)
12.3.8.    Rest of APAC
12.3.8.1.    Market Revenue Forecast (2016-2027)
12.4.    LATAM
12.4.1.    Market Revenue Forecast by System (2016-2027)
12.4.2.    Market Revenue Forecast by Container (2016-2027)
12.4.3.    Market Revenue Forecast by Application (2016-2027)
12.4.4.    Market Revenue Forecast by End User (2016-2027)
12.4.5.    Brazil
12.4.5.1.    Market Revenue Forecast (2016-2027)
12.4.6.    Rest of LATAM
12.4.6.1.    Market Revenue Forecast (2016-2027)
12.5.    Middle East and Africa (MEA)
12.5.1.    Market Revenue Forecast by System (2016-2027)
12.5.2.    Market Revenue Forecast by Container (2016-2027)
12.5.3.    Market Revenue Forecast by Application (2016-2027)
12.5.4.    Market Revenue Forecast by End User (2016-2027)
12.5.5.    GCC
12.5.5.1.    Market Revenue Forecast (2016-2027)
12.5.6.    North Africa
12.5.6.1.    Market Revenue Forecast (2016-2027)
12.5.7.    South Africa
12.5.7.1.    Market Revenue Forecast (2016-2027)
12.5.8.    Rest of MEA
12.5.8.1.    Market Revenue Forecast (2016-2027)

Chapter 13.    Company Profiles

13.1.    Johnson & Johnson, Inc.
13.1.1.    Company Overview, Business Information, Regional Presence
13.1.2.    Product Portfolio Analysis
13.1.2.1.    Product Details, Specification, Application
13.1.3.    Revenue, Price, and Gross Margin (2015-2020)
13.1.4.    Recent Developments and Strategies
13.2.    Aptar Pharma Group
13.2.1.    Company Overview, Business Information, Regional Presence
13.2.2.    Product Portfolio Analysis
13.2.2.1.    Product Details, Specification, Application
13.2.3.    Revenue, Price, and Gross Margin (2015-2020)
13.2.4.    Recent Developments and Strategies
13.3.    GlaxoSmithKline Plc
13.3.1.    Company Overview, Business Information, Regional Presence
13.3.2.    Product Portfolio Analysis
13.3.2.1.    Product Details, Specification, Application
13.3.3.    Revenue, Price, and Gross Margin (2015-2020)
13.3.4.    Recent Developments and Strategies
13.4.    Aegis Therapeutics LLC
13.4.1.    Company Overview, Business Information, Regional Presence
13.4.2.    Product Portfolio Analysis
13.4.2.1.    Product Details, Specification, Application
13.4.3.    Revenue, Price, and Gross Margin (2015-2020)
13.4.4.    Recent Developments and Strategies
13.5.    H&T Presspart Manufacturing Ltd.
13.5.1.    Company Overview, Business Information, Regional Presence
13.5.2.    Product Portfolio Analysis
13.5.2.1.    Product Details, Specification, Application
13.5.3.    Revenue, Price, and Gross Margin (2015-2020)
13.5.4.    Recent Developments and Strategies
13.6.    AstraZeneca Plc
13.6.1.    Company Overview, Business Information, Regional Presence
13.6.2.    Product Portfolio Analysis
13.6.2.1.    Product Details, Specification, Application
13.6.3.    Revenue, Price, and Gross Margin (2015-2020)
13.6.4.    Recent Developments and Strategies
13.7.    Becton, Dickinson and Company
13.7.1.    Company Overview, Business Information, Regional Presence
13.7.2.    Product Portfolio Analysis
13.7.2.1.    Product Details, Specification, Application
13.7.3.    Revenue, Price, and Gross Margin (2015-2020)
13.7.4.    Recent Developments and Strategies
13.8.    Novartis AG
13.8.1.    Company Overview, Business Information, Regional Presence
13.8.2.    Product Portfolio Analysis
13.8.2.1.    Product Details, Specification, Application
13.8.3.    Revenue, Price, and Gross Margin (2015-2020)
13.8.4.    Recent Developments and Strategies
13.9.    Teleflex Incorporated
13.9.1.    Company Overview, Business Information, Regional Presence
13.9.2.    Product Portfolio Analysis
13.9.2.1.    Product Details, Specification, Application
13.9.3.    Revenue, Price, and Gross Margin (2015-2020)
13.9.4.    Recent Developments and Strategies
13.10.    Vectura Group Plc.
13.10.1.    Company Overview, Business Information, Regional Presence
13.10.2.    Product Portfolio Analysis
13.10.2.1.    Product Details, Specification, Application
13.10.3.    Revenue, Price, and Gross Margin (2015-2020)
13.10.4.    Recent Developments and Strategies

Chapter 14.    Appendix

14.1.    About Us
14.2.    Glossary of Terms

Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.

Purchase Full Research Report (Single User License US$ 4500) @ https://www.precedenceresearch.com/checkout/1253

About Us

Precedence Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally.

Contact Us:         

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: sales@precedenceresearch.com

For Latest Update Follow Us:

https://www.linkedin.com/company/precedence-research/

https://www.facebook.com/precedenceresearch/

https://twitter.com/Precedence_R

Precedence Research

Precedence Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings.

Related Articles

Back to top button